5 курс / Психиатрия и наркология для детей и взрослых (доп.) / Психиатрия_Национальное_руководство_Александровский
.pdfс диагнозом рекуррентного депрессивного расстройства // Соц. и клин. психиатрия. 2015. Т. 25, вып. 1.
С. 22-30.
35. Паничева Е.В. Популяционное исследование периодических эндогенных психозов (демографические данные и сравнительная характеристика течения) //
Журн.
невропатол. и психиатр. 1982. Т. 82, № 4. С. 557-564.
36.Пантелеева Г.П., Раюшкин В.А., Снедкова Л.В. Некоторые подходы к оптимизации профилактической терапии аффективных психозов // Материалы XII съезда психиатров России. М., 1995. С. 542-543.
37.Тиганов А.С., Снежневский А.В., Орловская Д.Д. и др. Руководство по психиатрии / под ред. А.С. Тиганова. М. : Медицина, 1999.
38.Ушкалова А.В., Костюкова Е.Г., Мосолов С.Н. Проблемы диагностики и терапии биполярной депрессии: от доказательных научных исследований к клиническим рекомендациям. // Биологические методы терапии психических расстройств: доказательная медицина - клинической практике / под ред. С.Н. Мосолова. М., 2012. С. 491-529.
39.Федотов Д.Д., Костюкова Е.Г., Ладыженский М.Я., Мосолов С.Н. (ред.) Профилактическое применение вальпроата натрия, ламотриджина и топирамата у больных с биполярным аффективным расстройством с частыми рецидивами // Биологические методы терапии психических расстройств: доказательная медицина
-клинической практике. М., 2012. - С. 586-623.
40.Шафаренко А.А., Капилетти С.Г., Мосолов С.Н. Сравнительная эффективность и переносимость атипичных антипсихотиков при купировании маниакальных состояний в рамках шизоаффективного и биполярного расстройств // Соц. и клин. психиатрия.
2011. Т. 21, № 3. С. 58-65.
41.Шафаренко А.А., Мосолов С.Н. Современная терапия маниакальных и маниакально-бредовых состояний: от доказательных научных исследований к клиническим рекомендациям // Биологические методы терапии психических расстройств: доказательная медицина - клинической практике / под ред. С.Н. Мосолова. М., 2012. С.
554-585.
781
42.Ahlfors U.G., Baastrup P.C., Dencker S.J. et al. Neuroleptic induced extrapyramidal side effects in bipolar and schizophrenic patients // Acta Psychiatr. Scand. 1981. Vol. 64, N
3.P. 226-237.
43.Akiskal H.S. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV // J. Clin. Psychopharmacol. 1996. Vol. 16, suppl. 1. P. 4S-14S.
44.Akiskal H.S., Pinto O. The evolving bipolar spectrum: prototypes I, II, III, and IV // Psychiatr. Clin. North Am. 1999. Vol. 22. P. 517-534.
45.American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (5th version). Washington : American Psychiatric Association, 2013.
46.American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) // Am. J. Psychiatry. 2002. Vol. 159, N 4. Suppl. P. 1-50.
47.Angst J. Course of affective disorders // Handbook of Biological Psychiatry / eds van H.M. Praag, H.M. Lader, O.J. Rafaelson, E.J. Sachar. New York : Marcel Dekker, 1981. P.
225-242.
48.Angst J. The emerging epidemiology of hypomania and bipolar II disorder // J. Affect Disord. 1998. Vol. 50. P. 143-151.
49.Angst J., Adolfsson R., Benazzi F. et al. The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatients // J. Affect Disord. 2005. Vol. 88, N 22. P. 217-
50.Angst J., Gamma A., Benazzi F., Ajdacic V. et al. Diagnostic issues in bipolar disorder // Eur. Neuropsychopharmacol. 2003. Vol. 13. P. S43-S50.
51.Angst J., Sellaro R. Historical perspectives and natural history of bipolar disorder // Biol. Psychiatry. 2000. Vol. 48. P. 445-457.
52.Angst J., Stassen H.H., Clayton P.J. et al. Mortality of patients with mood disorders: follow up over 34-38 years// J. Affect. Disord. 2002. Vol. 68. P. 167-181.
53.Arnold O.H. Beobachtungen zum «automatenhaften Dasein» unter Lithium langzeit Therapie // Arzneimittelforshung. 1974. Bd 34. S. 1125-1127.
54.Azorin J.M. [Major depression: features indicative of bipolarity?] // Encephale. 2011. Vol. 37, suppl. 3. P. S163-S168.
55.Baastrup P.C. The use of lithium in manic-depressive psychosis // Compr. Psychiatry 1964. Vol. 10, N 5. P. 396-408.
56.Baastrup P.C., Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis // Arch. Gen. Psychiatry. 1967. Vol. 16.
782
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
P. 162-172.
57.Baillarger J. De la folie a' double forme // Ann. Med. Psychol. 1854. Vol. 6. P. 369-384.
58.Balarman Y., Lahiri D.K., Nurnberger J.I. Variants in ion channel genes link phenotypic features of bipolar illness to specific neurobiologocal process domains // Mol. Neuropsychiatry. 2015. Vol. 1. P. 23-35.
59.Baldessarini R.J., Tondo L., Viguera A.C. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications // Bipolar Disord. 1999. Vol. 1, N 1. P. 17-24.
60.Ballenger J.C., Post R.M. Carbamazepine in manic-depressive illness: A new treatment // Am. J. Psychiatry. 1980. Vol. 137. P. 782-790.
61.Benazzi F. Bipolar disorder - focus on bipolar II disorder and mixed depression // Lancet. 2007. Vol. 369. P. 935-945.
62.Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management // CNS Drugs. 2007. Vol. 21, N 9. P. 727-740.
63.Berk M., Hallam K., Lucas N. et al. Early intervention in bipolar disorders: opportunities
and pitfalls // Med. J. Aust. 2007. Vol. 187, suppl. 7. P. 11-14.
64.Beynon S., Soares-Weiser K., Woolacott N., Duffy S. et al. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials // J. Psychopharmacol. 2009. Vol. 23. P. 574-591.
65.Bowden C.L. Key treatment studies of lithium in manic-depressive illness: efficacy
and
side effects. // J. Clin. Psychiatry. 1998. Vol. 59, suppl. 6. P. 13-19, discussion P. 20.
66.Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression // Psychiatr Serv.
2001. Vol. 52. P. 51-55.
67.Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L. et al. A randomized, placebocontrolled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group // Arch. Gen. Psychiatry. 2000. Vol. 57.
P. 481-489.
68.Bowden C.L., Calabrese J.R., Sachs G. et al. A randomized, placebo-controlled 18month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder // Scientific Abstracts of the 40th Annual
783
Meeting of the American College of Neuropsychopharmacology. Waikoloa, HI, Dec 9-
13, 2001. P. 238.
69.Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N. et al. A placebo-controlled 18month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder // Arch. Gen. Psychiatry. 2003. Vol. 60. P.
392-400.
70.Bowden C.L., Ghaemi N., Gyulai L. et al. Lamotrigine delays mood episodes in recently depressed bipolar I patients // New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA, May 18-23, 2002. P.
71.Bowden C.L., Mosolov S., Hranov L., Chen E. et al Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12 week trial // Int. Clin. Psychopharmacol.
2010. Vol. 25, N 2. P. 60-67.
72.Bowden C.L., Singh V., Weisler R., Thompson P. et al. Lamotrigine vs lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression
// Acta Psychiatr. Scand. 2012. Vol. 126, N 5. P. 342-350.
73.Brown E.B., McElroy S.L., Keck P.E. Jr et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression // J. Clin. Psychiatry. 2006. Vol. 67, N 7. P. 1025-1033.
74.Bruce R., Culpepper L. et al. Quetiapine Monotherapy as Treatment for Anxiety Symptoms in Patients with Bipolar Depression: A Pooled Analysis of Results From 2 Double-Blind, Randomized, Placebo-Controlled Studies Pooled Analysis of Quetiapine for Bipolar
Depression. April 27, 2008. Accepted July 2, 2008. doi: 10.4088/PCC.08m00659.
75.Calabrese J., Bowden C.L., Sachs G., Yatham L.N. et al.; for the Lamictal 605 Study group. A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder // J. Clin. Psychiatry. 2003.
Vol. 64. P. 1024.
76.Calabrese J.R., Deluccni G.A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder // Am. J. Psychiatry. 1990. Vol. 147. P. 431-434.
784
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
77.Calabrese J.R., Goldberg J.F., Ketter T.A., Suppes T. et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies
//
Biol. Psychiatry. 2006. Vol. 59. P. 1061-1064.
78.Calabrese J.R., Keck P.E. et al. A randomized, double blind, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression // Am. J. Psychiatry. 2005. Vol. 162,
N 7. P. 1351-1360.
79.Calabrese J.R., Shelton M.D., Bowden C.L. et al. Bipolar rapid cycling: focus on depression as its hallmark // J. Clin. Psychiatry. 2001. Vol. 62, suppl. 14. P. 34-41.
80.Calabrese J.R., Suppes T., Bowden C.L. et al. A double-blind, placebo-controlled prophylaxis study of lamotrigine in rapid-cycling bipolar disorder // J. Clin. Psychiatry. 2000.
Vol. 61. P. 841-850.
81.Carvalhoa A.F., McIntyreb R.S., Dimelisc D. et al. Predominant polarity as a course specifier for bipolar disorder: a systematic review // J. Affect. Disord. 2014. Vol. 163C. P.
56-64.
82.Christensen M.V., Kyvik K.O., Kessing L.V. Cognitive function in unaffected twins discordant for affective disorder // Psychol. Med. 2006. Vol. 36. P. 1119-1129.
83.Cipriani A., Rendell J., Geddes J.R. Olanzapine in long-term treatment of bipolar disorder: a systematic review and meta-analysis // J. Psychopharmacol. 2010. Vol. 24, N
P. 1729-1738.
84.Clark L., Iversen S.D., Goodwin G.M. Sustained attention deficit in bipolar disorder // Br. J. Psychiatry. 2002. Vol. 180. P. 313-319.
85.Coppen A., Nogгuern R., Bailey J. et al. Prophylactic lithium in affective disorders: controlled trial // Lancet. 1971. Vol. 2. P. 275-279.
86.Coryell W., Endicott J., Maser J.D. et al. Long term stability of polarity distinctions in the affective disorders // Am. J. Psychiatry. 1995. Vol. 152. P. 385-390.
87.Cruz N., Sanchez-Moreno J. et al. Efficacy of modern antipsychotics in placebocontrolled trials in bipolar depression: a meta-analysis // Int. J. Neuropsychopharmacol. 2009. Vol. 29. P. 1-10.
88.Cundall R.L., Brooks P.W. and Murray L.G. A controlled evaluation of lithium prophylaxis in affective disorders // Psychol. Med. 1972. Vol. 2. P. 308-311.
785
89.Denicoff K.D., Smith-Jackson E.E., Disney E.R., Ali S.O. et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder // J. Clin.
Psychiatry. 1997. Vol. 58. P. 470-478.
90.Diagnosing, Assessing and Managing Bipolar Disorder in Adults in Secondary Care. Nice, 2015. URL:http://pathways.nice.org.uk/pathways/bipolar-disorder.
91.Dunner D.L., Fleiss J.L. and Fieve R.R. Lithium carbonate prophylaxis failure // Br.
J.
Psychiatry. 1976. Vol. 129. P. 40-44.
92.Eads L.A., Kramer T. Effects of topiramate on global functioning in treatmentrefractory mood disorders // Abstract submitted to the 22nd Congress of the Collegium Internationale Neuro-Psychopharmacolgicum. Brussels, 2000.
93.Ehnvall A., Agren H. Patterns of sensitisation in the course of affective illness. A life charting study of treatment refractory depressed patients // J. Affect. Disord. 2002. Vol.
P. 67-75.
94.Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizoaffective psychotics // Br. J. Psychiatry. 1985. Vol. 147. P. 198-200.
95.Emrich H.M., Dose M., Von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders // J. Affect. Disord. 1985. Vol. 8. P.
243-250.
96.Falret J.P. De la folie circulaire ou forme de maladie mentale caractérisée par l'alternative régulie`re de la manie et de la mélancholie // Bull. Acad. Med. (Paris). 1854. Vol. 19. P. 382.
97.Fiedorowicz J.G., Endicott J., Leon A.C. et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder // Am. J. Psychiatry. 2011.
Vol. 168. P. 40-48.
98.Fieve R.R., Kumbaraci R., Dunner D.L. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients // Am. J. Psychiatry. 1976. Vol. 133, N 8. P. 925-929.
99.Forty L., Smith D., Jones L. et al. Identifying hypomanic features in major depressive disorder using the hypomania checklist (HCL-32) // J. Affect. Dis. 2009. Vol. 114. P. 68-
786
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
100.Frye M.A., Altshuler L.L., McElroy S.L. et al. Gender differences in prevalence, risk and clinical correlate of alcoholism comorbidity in bipolar disorder // Am. J. Psychiatry.
2003. Vol. 160. P. 883-889.
101.Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T. et al. A placebo-controlled
study of lamotrigine and gabapentin monotherapy in refractory mood disorders // J. Clin.
Psychopharmacol. 2000. Vol. 20, N 6. P. 607-614.
102.Gelenberg A.J., Kane J.M., Keller M.B. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders // N. Engl. J. Med. 1989. Vol. 321.
P. 1489-1493.
103.Ghaemi S.N., Boiman E.E., Goodwin F.K. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study // J. Clin. Psychiatry. 2000. Vol. 61, N 10. P. 804-808.
104.Ghaemi S.N., Goodwin F.K. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs lithium in the setting of minimal antidepressant use // J.
Affect. Disord. 2001. Vol. 65, N 3. P. 281-287.
105.Ghaemi S.N., Manwani S.G., Katzow J.J., Ko J.Y. et al. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review // Ann. Clin. Psychiatry. 2001. Vol.
13.P. 185-189. doi: 10.1023/A:1014627001201/
106.Gitlin M. Lithium and the kidney: an updated review // Drug Saf. 1999. Vol. 20. P. 231-243.
107.Goldberg J.F., Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up // J. Affect. Disord. 2004. Vol.
P. 123-131.
108.Goncalves N., Stoll K.-D. Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppel-blind-Studie // Nervenarzt. 1985. Vol. 56. P. 43-47.
109.Goodwin F.K., Jamison K.R. Manic Depressive Illness. New York : Oxford University
Press, 1990. P. 369-596.
787
110.Goodwin G.M., Bowden C.L., Calabrese J.R., Grunze H. et al. A pooled analysis of
2placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder // J. Clin. Psychiatry. 2004. Vol. 65. P. 432-441.
111.Goodwin G.M., Martinez-Aran A., Glahn D.C. et al. Cognitive Impairment in Bipolar Disorder: Neurodevelopment or Neurodegeneration? An ECNP expert meeting report // Eur.
Neuropsychopharmacol. 2008. Vol. 18. P. 787-793.
112.Goswami U., Basu S., Khastgir U. et al. Neurobiological characterization of bipolar affective disorders: a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity // Indian J. Psychiatry. 1998. Vol. 40, N 3. P. 201-211.
113.Greil W., Ludwig-Mayerhofer W., Erazo N., Engel R.R. et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study // J. Affect.
Disord. 1997. Vol. 43. P. 151-161.
114.Guscott R. Clinical experience with valproic acid in 22 patients with refractory bipolar
mood disorder // Can. J. Psychiatry. 1992. Vol. 37, N 8. P. 590.
115.Gyulai L., Bowden C.L., McElroy S.L., Calabrese J.R. et al. Maintenance efficacy of divalproex in the prevention of bipolar depression // Neuropsychopharmacology. 2003. Vol.
28.P. 1374-1382.
116.Hakkaart-van Roijen L., Hoeijenbos M.B., Regeer E.J. et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands // Acta Psychiatr.
Scand. 2004. Vol. 110, N 5. P. 383-392.
117.Hirschfeld R., Keck P., Karcher K., Kramer M. et al. Rapid antimanic effect of risperidone monotherapy A 3-week multicenter, double-blind, placebo-controlled trial // Bipolar Disord. 2003. Vol. 5, suppl. 1. P. 60.
118.Hirschfeld R.M., Calabrese J.R., Weissman M. et al. Lifetime prevalence of bipolar I and II disorders in the United States [abstract] // Presented at the 155th American Psychiatric Association Annual Meeting. Philadelphia, PA, May 18-23, 2002.
119.Hirschfeld R.M., Lewis L., Vornik L.A. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive
788
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
Association 2000 survey of individuals with bipolar disorder // J. Clin. Psychiatry. 2003.
Vol.
64. P. 161-174.
120.Hirschfeld R.M., Williams J.B., Spitzer R.L. et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire // Am. J. Psychiatry. 2000. Vol. 157. P. 1873-1875.
121.Holma K.M., Haukka J., Suominen K. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder // Bipolar Disord. 2014. Vol. 16. P. 652-661.
122.Houston J.P., Ahl J. et al. Reduced suicidal ideation in bipolar I disorder mixedepisode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex // J. Clin. Psychiatry. 2006. Vol. 67, N 8. P. 1246-1252.
123.Hranov L., Marinova P., Stoyanova M. et al. Bipolar disorder - from endophenotypes
to treatment // Psychiatria Danubina. 2013. Vol. 25, N 3. P. 284-291.
124.Hwu H.G., Yeh E.K., Chang L.Y. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule // Acta Psychiatr. Scand. 1989. Vol.
79.P. 136-147.
125.Judd L.L., Akiskal H.S. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder // Curr. Psychiatry Rep. 2003. Vol. 5, N 6. P. 417-
126.Judd L.L., Akiskal H.S., Schettler P.J. et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder // Arch. Gen. Psychiatry. 2002. Vol. 59, N
6.P. 530-537
127.Judd L.L., Schettler P.J., Akiskal H.S. et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders // Int. J. Neuropsychopharmacol. 2003. Vol. 6. P. 127-
128.Kapczinski F., Vieta E., Andreazza A.C. et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment // Neurosci. Biobehav. Rev. 2008. Vol.
P. 675-692.
129.Keck P.E. Jr, Calabrese J.R. et al. A randomized, double-blind, placebo-controlled 26week trial of aripiprazole in recently manic patients with bipolar I disorder // J. Clin.
789
Psychiatry. 2006. Vol. 67, N 4. P. 626-637.
130.Keck P.E. Jr, Calabrese J.R., McIntyre R.S. et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
//
J. Clin. Psychiatry. 2007. Vol. 68, N 10. P. 1480-1491.
131.Keck P.E., McElroy S.L., Strakowski SM et al. Outcome and comorbidity in firstepisode compared with multiple-episode mania // J. Nerv. Ment. Dis. 1995. Vol. 183. P. 320-324.
132.Kessing L.V. Recurrence in affective disorders // Br. J. Psychiatry. 1998. Vol. 172. P. 23-28.
133.Kessler R.C., McGonagle K.A., Zhao S. et al. Lifetime and 12-month prevalence of DMS-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey // Arch. Gen. Psychiatry.1994. Vol. 51, N 1. P. 8-19.
134.Kessler R.C., Stang P, Wittchen HU et al. Lifetime co-morbidities between social phobia and mood dis-i in the US National Comorbidity Survey // Psychol. Med. 1999. Vol.
29.P. 555-567.
135.Kogan J.N., Otto M.W., Bauer M.S. et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (sTEP-BD) // Bipolar Disord. 2004. Vol. 6, N 6. P. 460-469.
136.Koukopoulos A., Reginaldi D., Tondo L. et al. Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias // J. Affect. Disord. 2013. Vol.
151.P. 105-110.
137.Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh : E & S Livingstone,
1921.
138.Kravitz H.M., Fawcett J. Carbamazepine in the treatment of affective disorders // Med. Sci. Res. 1987. Vol. 15. P. 1-8.
139.Kudryakova T.B., Kostyukova E.G. et al. Possible relationships between carbamazepine metabolites levels and prophylactic efficacy // Hum. Psychopharmacol. 1992. Vol. 7. P.
135-138.
790
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/